Closed |
S1312 |
PI/II Inotuzumab + CVP for R/R CD22+ ALL |
4/1/2014 |
8/2/2019 |
100% |
|
|
Closed |
S1320 |
Melanoma - Ph II Intermittent vs Continuous Dabrafenib and Trametinib BRAF Positive Melanoma |
7/22/2014 |
7/15/2019 |
100% |
|
|
Closed |
S1416 |
Ph II Cisplatin +/- ABT 888 in Metastatic TNBC and/or BRCA |
7/7/2016 |
6/15/2019 |
100% |
|
|
Closed |
S1207 |
Ph. III Randomized, Everolimus in high risk, hormone receptor positive, HER2 negative patients. |
9/3/2013 |
5/1/2019 |
100% |
|
|
Closed |
S1417CD |
Impact of Cancer on Finances |
4/15/2016 |
2/1/2019 |
100% |
|
|
Closed |
S1400K |
Lung-MAP S1400K: c-MET Positive |
2/5/2018 |
12/21/2018 |
64% |
|
|
Closed |
S1400G |
Lung-MAP S1400G: HRRD - Talazoparib (BMN 673) |
2/7/2017 |
7/23/2018 |
85% |
|
|
Closed |
S1403 |
Lung Ph II/III Stage IV NSCLC Afatinib+Cetuximab vs Afatinib |
3/25/2015 |
4/23/2018 |
29% |
|
|
Closed |
S1400I |
Lung-MAP S1400I: Non-Match, Nivolumab + Ipilimumab |
12/18/2015 |
4/23/2018 |
79% |
|
|
Closed |
S1507 |
Ph II Tram + doce with kras NSCLC + and PD |
7/18/2016 |
3/15/2018 |
100% |
|
|
Closed |
S1314 |
Phase II COXEN Trial for Localized Bladder Cancer |
7/9/2014 |
12/1/2017 |
100% |
|
|
Closed |
S0919 |
Phase II Idarubicin/AraC + Pravastatin for Relapsed AML |
8/15/2009 |
9/15/2017 |
100% |
|
|
Closed |
S1216 |
Metastatic Prostate Cancer, Phase III ADT+TAK-700 vs. ADT+Bicalutamide |
3/1/2013 |
7/15/2017 |
100% |
|
|
Closed |
S1011 |
Muscle-Invasive Bladder Ca, Std vs Ext PLND, Ph III |
8/1/2011 |
4/15/2017 |
100% |
|
|
Closed |
S1204 |
Viral Screening Study |
8/29/2013 |
2/15/2017 |
100% |
|
|
Closed |
S1400B |
Lung-MAP S1400B: PI3K - GDC-0032 |
6/15/2014 |
12/12/2016 |
57% |
|
|
Closed |
S1400D |
Lung-MAP S1400D: FGFR - AZD4547 |
6/15/2014 |
10/31/2016 |
81% |
|
|
Closed |
S1013 |
EGFR Skin Toxicity Validation |
11/15/2011 |
10/1/2016 |
94% |
|
|
Closed |
S0931 |
Adjuvant Renal Cell, Everolimus vs Placebo, Ph III |
4/1/2011 |
9/15/2016 |
100% |
|
|
Closed |
S1300 |
Rand Ph II of Crizotinib + Pem vs Pem in ALK+ NSCLC Pts Progressing Post Crizotinib |
8/1/2014 |
9/1/2016 |
1% |
|
|